Quantitative determination of farnesyl and geranylgeranyl diphosphate levels in mammalian tissue

Analytical Biochemistry

Volumn 378, Issue 2, 2008, Pages 138-143

  Tong, Huaxiang ^a   Wiemer, Andrew J ^b   Neighbors, Jeffrey D ^a,c   Hohl, Raymond J ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c Terpenoid Therapeutics   (United States)

Author keywords

Bisphosphonate; Farnesyl diphosphate; Fluorescence detection; Geranylgeranyl diphosphate; High performance liquid chromatography; Isoprenoid diphosphate; Mevalonate; Mouse tissue; Pyrophosphate

Indexed keywords

BIOCHEMISTRY; BIOSYNTHESIS; EXTRACTION; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; LIPIDS; LIQUEFIED GASES; MAMMALS; PHASE SEPARATION; PROTEINS;

BISPHOSPHONATES; DIPHOSPHATES; FARNESYL DIPHOSPHATE; FLUORESCENCE DETECTION; GERANYLGERANYL DIPHOSPHATE; MEVALONATE; MOUSE TISSUES; PYROPHOSPHATE;

TISSUE;

FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; ISOPRENOID; LIQUID NITROGEN; PROTEIN FARNESYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASSAY; BIOSYNTHESIS; BRAIN TISSUE; FLUORESCENCE; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY PARENCHYMA; LIVER; MALE; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOLID PHASE EXTRACTION; TISSUE TYPES;

MAMMALIA; MUS;

EID: 44649156936     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2008.04.021     Document Type: Article

References (39)

1. Holstein S.A., and Hohl R.J. Isoprenoids: Remarkable diversity of form and function. Lipids 39 (2004) 293-309
2. Popjak G., and Agnew W.S. Squalene synthetase. Mol. Cell. Biochem. 27 (1979) 97-116
3. Liang P.H., Ko T.P., and Wang A.H. Structure, mechanism, and function of prenyltransferases. Eur. J. Biochem. 269 (2002) 3339-3354
4. Zhang F.L., and Casey P.J. Protein prenylation: Molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65 (1996) 241-269
5. Hori Y., Kikuchi A., Isomura M., Katayama M., Miura Y., Fujioka H., Kaibuchi K., and Takai Y. Post-translational modifications of the C-terminal region of the rho protein are important for its interaction with membranes and the stimulatory and inhibitory GDP/GTP exchange proteins. Oncogene 6 (1991) 515-522
6. Swanson K.M., and Hohl R.J. Anti-cancer therapy: Targeting the mevalonate pathway. Curr. Cancer Drug Targets 6 (2006) 15-37
7. Grundy S.M. Drug therapy: HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med. 319 (1988) 24-33
8. Reszka A.A., and Rodan G.A. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev. Med. Chem. 4 (2004) 711-719
9. Charlton-Menys V., and Durrington P.N. Squalene synthase inhibitors: Clinical pharmacology and cholesterol-lowering potential. Drugs 67 (2007) 11-16
10. Basso A.D., Kirschmeier P., and Bishop W.R. Farnesyl transferase inhibitors. J. Lipid Res. 47 (2006) 15-31
11. El Oualid F., Cohen L.H., van der Marel G.A., and Overhand M. Inhibitors of protein: Geranylgeranyl transferases. Curr. Med. Chem. 13 (2006) 2385-2427
12. Wiemer A.J., Yu J.S., Lamb K.M., Hohl R.J., and Wiemer D.F. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorg. Med. Chem. 16 (2008) 390-399
13. Wiemer A.J., Yu J.S., Shull L.W., Barney R.J., Wasko B.M., Lamb K.M., Hohl R.J., and Wiemer D.F. Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation. Bioorg. Med. Chem. 16 (2008) 3652-3660
14. Thompson K., Gordon S.A., and Rogers M.J. N-Bisphosphonates stimulate proliferation of γ/δ-T cells in human PBMC cultures by inhibiting the mevalonate pathway: Clarification of the acute phase response. J. Bone Miner. Res. 17 (2002) S199
15. Sanders J.M., Ghosh S., Chan J.M., Meints G., Wang H., Raker A.M., Song Y., Colantino A., Burzynska A., Kafarski P., Morita C.T., and Oldfield E. Quantitative structure-activity relationships for γ/δ T cell activation by bisphosphonates. J. Med. Chem. 47 (2004) 375-384
16. Bergstrom J.D., Kurtz M.M., Rew D.J., Amend A.M., Karkas J.D., Bostedor R.G., Bansal V.S., Dufresne C., VanMiddlesworth F.L., Hensens O.D., Liesch J.M., Zink D.L., Wilson K.E., Onishi J., Milligan J.A., Bills G., Kaplan L., Omstead M.N., Jenkins R.G., Huang L., Meinz M.S., Quinn L., Burgh R.W., Kong Y.L., Mochales S., Mojena M., Martin I., Pelaez F., Diez M.T., and Alberts A.W. Zaragozic acids: A family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sci. USA 90 (1993) 80-84
17. Gonzalez-Pacanowska D., Arison B., Havel C.M., and Watson J.A. Isopentenoid synthesis in isolated embryonic Drosophila cells: Farnesol catabolism and omega-oxidation. J. Biol. Chem. 263 (1988) 1301-1306
18. Tong H., Holstein S.A., and Hohl R.J. Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Anal. Biochem. 336 (2005) 51-59
19. Dudakovic A., Wiemer A.J., Lamb K.M., Vonnahme L.A., Dietz S.E., and Hohl R.J. Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes. J. Pharmacol. Exp. Ther. 324 (2008) 1028-1036
20. Edwards P.A., and Ericsson J. Sterols and isoprenoids: Signaling molecules derived from the cholesterol biosynthetic pathway. Annu. Rev. Biochem. 68 (1999) 157-185
21. Salerno-Kennedy R., and Cashman K.D. Potential applications of breath isoprene as a biomarker in modern medicine: A concise overview. Wien. Klin. Wochenschr. 117 (2005) 180-186
22. Sehnert S.S., Jiang L., Burdick J.F., and Risby T.H. Breath biomarkers for detection of human liver diseases: Preliminary study. Biomarkers 7 (2002) 174-187
23. Parentini I., Cavallini G., Donati A., Gori Z., and Bergamini E. Accumulation of dolichol in older tissues satisfies the proposed criteria to be qualified a biomarker of aging. J. Gerontol. A 60 (2005) 39-43
24. Bruenger E., and Rilling H.C. Determination of isopentenyl diphosphate and farnesyl diphosphate in tissue samples with a comment on secondary regulation of polyisoprenoid biosynthesis. Anal. Biochem. 173 (1988) 321-327
25. Keller R.K. Squalene synthase inhibition alters metabolism of nonsterols in rat liver. Biochim. Biophys. Acta 1303 (1996) 169-179
26. Saisho Y., Morimoto A., and Umeda T. Determination of farnesyl pyrophosphate in dog and human plasma by high-performance liquid chromatography with fluorescence detection. Anal. Biochem. 252 (1997) 89-95
27. Wiemer A.J., Tong H.X., Swanson K.M., and Hohl R.J. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Biochem. Biophys. Res. Commun. 353 (2007) 921-925
28. Murthy S., Tong H., and Hohl R.J. Regulation of fatty acid synthesis by farnesyl pyrophosphate. J. Biol. Chem. 280 (2005) 41793-41804
29. Jainchill J.L., Aaronson S.A., and Todaro G.J. Murine sarcoma and leukemia viruses: Assay using clonal lines of contact-inhibited mouse cells. J. Virol. 4 (1969) 549-553
30. Koeffler H.P., and Golde D.W. Human myeloid leukemia cell lines: A review. Blood 56 (1980) 344-350
31. Keller R.K., Small M., and Fliesler S.J. Enzyme blockade: A nonradioactive method to determine the absolute rate of cholesterol synthesis in the brain. J. Lipid Res. 45 (2004) 1952-1957
32. Joly A., Popjak G., and Edwards P.A. In vitro identification of a soluble protein: geranylgeranyl transferase from rat tissues. J. Biol. Chem. 266 (1991) 13495-13498
33. Kotti T.J., Ramirez D.M., Pfeiffer B.E., Huber K.M., and Russell D.W. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc. Natl. Acad. Sci. USA 103 (2006) 3869-3874
34. Ericsson J., Runquist M., Thelin A., Andersson M., Chojnacki T., and Dallner G. Distribution of prenyltransferases in rat tissues: Evidence for a cytosolic all- trans -geranylgeranyl diphosphate synthase. J. Biol. Chem. 268 (1993) 832-838
35. Body J.J., Bartl R., Burckhardt P., Delmas P.D., Diel I.J., Fleisch H., Kanis J.A., Kyle R.A., Mundy G.R., Paterson A.H., and Rubens R.D. Current use of bisphosphonates in oncology: International Bone and Cancer Study Group. J. Clin. Oncol. 16 (1998) 3890-3899
36. Chan K.K., Oza A.M., and Siu L.L. The statins as anticancer agents. Clin. Cancer Res. 9 (2003) 10-19
37. Graaf M.R., Richel D.J., van Noorden C.J., and Guchelaar H.J. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat. Rev. 30 (2004) 609-641
38. Holstein S.A., Wohlford-Lenane C.L., and Hohl R.J. Isoprenoids influence the expression of Ras and Ras-related proteins. Biochemistry 41 (2002) 13698-13704
39. Holstein S.A., Wohlford-Lenane C.L., and Hohl R.J. Consequences of mevalonate depletion: Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB. J. Biol. Chem. 277 (2002) 10678-10682